UCLA Oncology Center

Los Angeles, California 90095

1 studies enrolling now · 10 studies all time

What they study most

Advanced Cancer, Advanced Solid Tumors, Astrocytoma, Glioma, Grade 2 Glioma, KRAS G12C Lung Cancer, Malignant Glioma, Melanoma, Myelodysplastic Syndrome, Neoplasms, Non-Small Cell Lung Cancer, Oligodendroglioma

Studies at this site

• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Recruiting now
• Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation — Completed
• Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) — Running, not enrolling
• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma — Completed
• First in Patient Study for PF-06840003 in Malignant Gliomas — Stopped early
• A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) — Completed
• Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors — Completed
• Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer — Stopped early
• A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer — Stopped early
• Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome — Status unconfirmed